The difference was largely the result of differences in patients with shock ( talactoferrin , 33/105 [ 31.4 % ] vs placebo , 21/104 [ 20.2 % ] ; p = 0.064 ) ; no mortality difference was seen in patients without shock ( talactoferrin , 5/48 [ 10.4 % ] vs placebo , 6/48 [ 12.5 % ] ; p = 0.806 ) .